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Background: Combined pegylated interferon-α and ribavirin therapy has sustained virological response (SVR) rates
of 54% to 61%. Pretreatment predictors of SVR to interferon therapy have not been fully investigated yet. The
current study assesses a group of chemokines that may predict treatment response in Egyptian patients with
chronic HCV infection.
Patients and methods: CXCL5, CXCL9, CXCL11, CXCL12, CXCL 13, CXCL 16 chemokines and E-Cadherin were
assayed in 57 chronic HCV patients’ sera using quantitative ELISA plate method. All studied patients were scheduled
for combined pegylated interferon alpha and ribavirin therapy (32 patients received pegylated interferon α 2b, and
25 patients received pegylated interferon α 2a). Quantitative hepatitis C virus RNA was done by real time RT-PCR
and HCV genotyping by INNOLIPAII.
Results: There was no significant difference (p > 0.05) in baseline HCV RNA levels between responders and
non-responders to interferon. A statistically significant difference in CXCL13 (p = 0.017) and E-Cadherin levels
(P = 0.041) was reported between responders and nonresponders at week 12. Significant correlations were found
between changes in the CXCL13 levels and CXCL9, CXCL16, E-cadherin levels as well as between changes in
E-cadherin levels and both CXCL16 and ALT levels that were maintained during follow up. Also, significant changes
have been found in the serum levels of CXCL5, CXCL13, and CXCL16 with time (before pegylated interferon α 2 a
and α 2 b therapy, and at weeks 12 and 24) with no significant difference in relation to interferon type and
response to treatment.
Conclusion: Serum levels of CXCL13 and E-Cadherin could be used as surrogate markers to predict response of
combined PEG IFN-α/RBV therapy, especially at week 12. However, an extended study including larger number of
patients is needed for validation of these findings.
Clinical trial No: NCT01758939
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Hepatitis C virus (HCV) is a major cause of a wide
spectrum of liver diseases ranging from mild chronic
hepatitis to end stage cirrhosis and hepatocellular car-
cinoma. The World Health Organization (WHO) esti-
mates that 170 million individuals worldwide are
infected with HCV [1], However, the prevalence of
HCV infection varies throughout the world. One decade* Correspondence: ncizekri@yahoo.com
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reproduction in any medium, provided the orago, Frank et al., reported that Egypt had the highest
number of reported HCV infections, largely attributed
to the use of contaminated parenteral antischistosomal
therapy [2]. The overall prevalence of HCV antibodies
in the Egyptian population was 15% for age of 15 to
59 years and infection was higher among rural residents
[3], and about 91% of the patients were infected with
HCV genotype 4 [4].
Combined pegylated interferon (IFN)-α and ribavirin
(RBV) therapy has sustained virological response (SVR)
rates reaching up to 61% in different clinical trials for
HCV Genotype 1 patients [5,6]. The therapeutic efficacyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immune-modulatory properties [7]. Factors associated
with SVR to interferon treatment have not been fully in-
vestigated in HCV genotype 4 infected patients. Previous
studies demonstrated that age, body weight, baseline
ALT, baseline HCV RNA viral load, HCV genotype and
the level of fibrosis or cirrhosis are some predictors of
response [8-12]. However, recent studies indicated that
cytokines could be used as markers for disease progres-
sion in HCV infected patients [13].
Some recent studies demonstrate that IL-8, and CXCL10
chemokines correlate with poor response to antiviral ther-
apy in CHC patients [13-15] or have prognostic utility as a
marker of treatment outcome [16-18]. Moreover, control
of HCV infection may depend in part on chemokine-
mediated recruitment of specific T cells to the liver [19]. In
this context, Moura et al., [17] evaluated the association
between pretreatment plasma levels of chemokines CCL2,
CCL3, CCL11, CCL24, CXCL9, CXCL10 and soluble
tumor necrosis factor receptors and the virological re-
sponse in CHC-treated patients. They found that pretreat-
ment CXCL10 level predicts EVR and SVR to IFN-α and
ribavirin and may therefore be useful in the evaluation of
candidates for therapy.
However, no previous studies have been done in Egypt
yet to assess the possible role of chemokines levels as
predictors of response to interferon therapy. The current
study aims to assess 1) the changes in serum levels of
CXCL5, CXCL9, CXCL11, CXCL12, CXCL 13, CXCL 16
chemokines and E-Cadherin in Egyptian patients with
chronic HCV genotype 4 infection who were recruited
for combined PEG IFN-α/RBV therapy at baseline and
after 12 and 24 weeks, and 2) to determine the utility of
using these markers as predictors of the treatment re-
sponse through determining the influence of therapy on
these chemokines.
Results
The current study was conducted on 57 CHC genotype-
4 patient s, of which 32 (56.1%) received pegylated inter-
feron α 2b, and 25 (30.4%) received pegylated interferon
α 2a. Clinical and laboratory findings of the studied
patients are shown in Table 1. There was no significant
difference between pegintron and pegasys patients re-
garding histopathological and laboratory findings (p >
0.05) except for the age (p=0.04).
Baseline mean values of HCV RNA Log (EQ/ML)
levels for the patients who received pegylated interferon
α2b (Peg-intron) and pegylated interferon α 2a (Pegasys)
were 5.4431 Log (EQ/ML) and 5.3824 Log (EQ/ML);
respectively.
Different baseline data that might affect achievement
of sustained virological response (SVR) such as age, body
mass index, AST, ALT, and viral load were analyzed forpegylated interferon α2b and α2a therapy. There was a
statistically significant difference between responders
and non-responders in the AFP value for patients who
received pegylated interferon α 2b (p=0.041) and α 2a
(p = 0.05) therapy. Also, there was a statistically signifi-
cant difference between responders and non-responders
in AST value for patients who received pegylated inter-
feron α2b (p=0.049) and α2a (0.001) therapy. On the
other hand, the other baseline data did not differ signifi-
cantly between the two studied groups (Table 2).
Serum levels of the studied chemokines in response to
pegylated interferon α2b and α2a therapy were deter-
mined before the beginning of treatment, after 12 and
24 weeks of treatment and correlated to the clinical data
and response to treatment. However, full clinical and
follow up data were available for 25 patients in group I (re-
ceiving Peg-intron) and 19 patients in group II (receiving
pegasys treatment) only (Table 3). Each group was divided
into two arms (responders and non-responders). As shown
in Table 3 and Figure 1 the serum pretreatment levels of
CXCL5 (1.275 ± 0.969 pg/ml) and (1.337 ± 0.792 pg/ml)
were significantly higher than those assessed either at 12
(0.711 ± 0.459 pg/ml) and (0.908 ± 0.588 pg/ml) or 24 weeks
(0.722 ± 0.466 pg/ml) and (0.951 ± .571 pg/ml) of pegylated
interferon α2b therapy for both non-responders and re-
sponders; respectively.
The same findings were observed in patients receiving
pegylated interferon α2 a therapy, since CXCL5 pretreat-
ment levels (1.220 ± 1.022 pg/ml) and (1.423 ± .925 pg/
ml) were significantly higher than those assessed either
after 12 (1.004 ± .699 pg/ml) and (0.808 ± 0.609 pg/ml)
or 24 weeks (0.766 ± 0.433 pg/ml) and (0.862 ± 0.634 pg/
ml) of non-responders and responders; respectively (p-
value = 0.0001). No significant difference was found in
relation to treatment type, response to treatment, time-
type interaction, time-response interaction, or type-
response interaction.
CXCL9 levels decreased in responders to pegylated
interferon α2b and α2a therapy after 12 and 24 weeks.
Whereas in non-responders, CXCL9 levels decreased at
12 weeks of therapy, then it increased at 24 weeks. No
significant difference was found for the effect of time,
treatment type, response to treatment, time-type inter-
action, time-response interaction, or type-response inter-
action (Table 3 and Figure 2).
Serum levels of CXCL11 were elevated in responders to
pegylated interferon α2b therapy at 12 and 24 weeks,
while it diminished at 12 weeks then increased at 24 weeks
for both responders and non-responders to pegylated
interferon α2a therapy. However, the difference was not
statistically significant in relation to the effect of time,
treatment type, response to treatment, time-type inter-
action, time-response interaction, or type-response inter-
action (Table 4 and Figure 3).
Table 1 Clinical and Laboratory findings of the studied
57 chronic hepatitis C patients




-Age 37.72 ± 8.44 42.28 ± 7.86 0.04
-BMI (Kg/m2) 26.35 ± 4.06 27.87 ± 4.13 0.17
-Male 27 (84.4%) 21 (84%) 0.96
-Female 5 (15.6%) 4 (16%)




A1 : 13 (40.6%) A1 : 8 (32%) 0.52
A2 : 10 (31.2%) A2 : 10 (40%)
A3 : 4 (12.5%) A3 : 5 (20%)
A4 : 2 (6.2%) A4 : 1 (4%)
-Fibrosis Missed: 3 (9.3%) Missed: 1 (4%)
F1: 17 (53.1%) F1: 10 (40%) 0.87
F2 : 4 (12.5%) F2 : 4 (16%)
F3 : 4 (12.5%) F3 : 3 (12%)
F4 : 2 (6.2%) F4 : 2 (8%)




S0 : 11 (34.3%) S0 : 11 (44%) 0.53
S1: 12 (37.5%) S1: 12 (48%)
S2: 7 (21.8%) S2: 7 (28%)
S3: 2 (6.2%) S3: 2 (8%)
III. Laboratory features (Mean ± SD)
HCV PCR Log (EQ/ML) 5.4431 5.3824 0.79
(before treatment)
WBC × 103/mm3 5.9344 ± 1.87266 6.1600 ±
2.55261
0.70
Hemoglobin (gm/dl) 14.3 ± 1.5 12.1 ± 1.1 0.67
Platelets count/mm3 212148 ± 76965 150868.8 ± 1.0 0.32
AST (0-42 IU/L) 60.1 ± 38.5 63.7200 ± 41.67 0.21
ALT (0-42 IU/L) 72.6 ± 50.4 88.5 ± 48.6 0.31
ALP (0-290 IU/L) 117.7 ± 67.7 93.9 ± 72.6 0.14
Total Bil(0.1-1.2 mg/dl) 0.81 ± 0.41 .7689 ± .311 0.81
Indirect Bil (mg/dl) 0.45 ± 0.80 .4526 ± 29238 0.69
Albumin (3.5-5.5gm/dl) 4.21 ± 0.43 3.62 ± 0.32 0.34
Prothrombin (%) 77.0 ± 27.0 71.1± 12.5 0.60
AFP (0-10 ng/ml) 16.50 ± 9.76 10.1± 4.7 0.10
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peg-intron therapy at 12 weeks and decreased in non-
responders. In patients receiving pegasys therapy, it de-
creased after 12 and 24 weeks, but no significant difference
was found for time change, treatment type, response totreatment, time-type interaction, time-response interaction,
or type-response interaction (Table 3 and Figure 4).
Serum pretreatment levels of CXCL13 (0.405 ± 0.274 pg/
ml and 0.298 ± 0.105 pg/ml) were significantly lower than
those evaluated either at 12 (0.529 ± 0.271 pg/ml and
0.341 ± 0.145 pg/ml) or 24 weeks (0.628 ± 0.455 pg/ml and
0.399 ± 0.128 pg/ml) in pegylated interferon α2a treated
patients for the non-responders and responders; respect-
ively (p = 0.002). Similarly, CXCL13 pretreatment levels
for responders of pegylated interferon α2b therapy
(0.315 ±0.105 pg/ml) were significantly lower than
those assessed either after 12 (0.433 ± 0.246 pg/ml) or
24 weeks (0.539 ±0.377 pg/ml). For the pegylated inter-
feron α2a nonresponders, CXCL13 levels increased at
12 weeks from 0.340 ± 0.069 to 0.504 ± 0.139 pg/ml
then, it decreased at 24 weeks to 0.473 ± 0.181 pg/ml
(Table 3 and Figure 5). However, no significant differ-
ence was found in relation to treatment type, response
to treatment, time type interaction, time-response in-
teraction, or type-response interaction.
Pretreatment levels of CXCL16 for non-responders to
pegylated interferon α2b and α2a therapy; respectively
(0.946 ± 0.101 and 1.146 ± 0.424 ng/ml) and responders
(0.874 ± 0.244 & 1.012 ± 0.331 ng/ml) were significantly
lower than those after 12 weeks for non-responders
(1.153 ± 0.298 & 1.254 ± 0.342 ng/ml), and responders
(1.110 ± 0.323 & 1.249 ± 0.417 ng/ml), or after 24 weeks
from the beginning of therapy for non-responders
(1.268 ± 0.353 & 1.291 ± 0.354 ng/ml) and responders
(1.139 ± 0.408 & 1.288 ± 0.402 ng/ml) (Table 3 and Figure 6).
However, no significant difference was found in rela-
tion to treatment type, response to treatment, time-
type interaction, time-response interaction, or type-
response interaction.
Serum levels of E-Cadherin increased observably in
non-responders and responders after 12 weeks from the
beginning of therapy (either Pegylated IFNα 2a or 2b
groups) and continued to increase at 24 weeks but in
responders only. No significant difference was found in
relation to time change, treatment type, response to
treatment, time-type interaction, timeresponse interaction,
or type-response interaction (Table 3 and Figure 7).
No significant correlation was found between the ex-
pression levels of any of the studied chemokines and
baseline HCV RNA in our studied patients.
Correlations between different chemokines
Before treatment initiation CXCL13 was significantly cor-
related to CXCL9 (r = 0.385, p = 0.003), CXCL16 (r =
0.366, p = 0.048) and E-cadherin (r = 0.511, p = 0.000).
While E-cadherin was significantly correlated to CXCL16
(r = 0.628, p = 0.000). Otherwise there was no significant
correlation between the others chemokine’s studied or be-
tween them and the baseline AST, ALT and albumin levels
Table 2 Baseline differences of Lab findings among responders and non-responders of Pegylated interferon α 2b
and α 2a therapy
Parameter Pegylated interferon α 2b P-
value
Pegylated interferon α 2a P-
valueNon-responders (n=10) Responders (n=22) Non-responders (n=13) Responders (n=12)
Age (Year) 38.70 ± 9.76 37.27 ± 7.98 0.66 43.69 ± 5.76 40.75 ± 9.37 0.35
BMI** (Kg/m2) 24.87 ± 4.63 27.02 ± 3.69 0.16 28.73 ± 3.99 26.93 ± 4.25 0.28
AST (0–42 IU/L) 39.20 ± 25.68 64.15 ± 30.54 0.049* 87.61 ± 43.13 37.83 ± 18.80 0.001*
ALT (0–42 IU/L) 44.12 ± 22.1 68.4 ± 21.1 0.07 46.42 ±14.13 43.56 ± 3.56 0.1
ALP (0–290 IU/L) 16.53 ± 9.7 4.66 ± 7.51 0.041* 13.94 ±15.38 4.24 ± 2.26 0.05*
HCV
PCR Log (EQ/ML) before treatment
5.3082 5.4975 0.61 5.5034 5.1751 0.29
*P value <0.05 considered significant, BMI** : Body Mass Index.
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and ALT level (r = 0.363, p = 0.048).
At 12 weeks of therapy E-cadherin was significantly
correlated to CXCL5 (r = 0.358, p = 0.047), CXCL9 (r =
0.311, p = 0.021), CXCL12 (r = 0.789, p = 0.000), CXCL13
(r = 0.583, p = 0.000), CXCL16 (r = 0.810, p = 0.000) and
ALT levels (r = 0.311, p = 0.021).
CXCL5 was significantly correlated to CXCL9 (r =
0.359, p = 0.007), CXCL11(r = 0.456, p = 0.000), CXCL12Table 3 Different chemokine’s levels of 44 patients in respon
Parameter Pegylated interferon α 2b
(PEG-INTRON) (n=25)
Non-responders (n=6) Responders
CXCL5(pg/ml) Pretreatment 1.27500 ± .969563 1.33774 ± .7
12 Weeks .71167 ± .459045 .90895 ± .58
24 Weeks .7220 ± .46685 .9518 ± .571
CXCL9(pg/ml) Pretreatment .19233 ± .114175 .20568 ± .07
12 Weeks .19233 ± .124331 .14284 ± .04
24 Weeks .13750 ± .072116 .18945 ± .12
CXCL11(pg/ml) Pretreatment .13520 ± .080444 .13945 ± .07
12 Weeks .15260 ± .081185 .16190 ± .09
24 Weeks .14883 ± .038071 .17705 ± .10
CXCL12(pg/ml) Pretreatment 84.69483 ± 206.396544 .39289 ± .15
12 Weeks .49400 ± .065023 .42263 ± .14
24 Weeks .373 ± .1015 .439 ± .1431
CXCL13(pg/ml) Pretreatment .34000 ± .069974 .31553 ± .10
12 Weeks .50483 ± .139194 .43342 ± .24
24 Weeks .47333 ± .181595 .53990 ± .37
CXCL16(ng/ml) Pretreatment .94633 ± .101567 .87458 ± .24
12 Weeks 1.15333 ± .298719 1.11037 ± .3
24 Weeks 1.26867 ± .353015 1.13953 ± .4
E-cadherin(ng/ml) Pretreatment .41983 ± .425530 .40989 ± .43
12 Weeks .72350 ± .666040 .55905 ± .57
24 Weeks .63783 ± .634553 .77832 ± .85
p-value comparing the effect of time a, treatment type b, response to treatment c, time(r = 0.417, p = 0.002), CXCL13 (r = 0.448, p = 0.001) and
CXCL16 (r = 0.326, p = 0.015). CXCL9 was significantly
correlated to CXCL12 (r = 0.640, p = 0.000), CXCL13 (r =
0.422, p = 0.001) and CXCL16 (r = 0.519, p = 0.000). CX
CL12 was significantly correlated to CXCL13 (r = 0.622,
p = 0.000) and CXCL16 (r = 0.827, p = 0.000). CXCL13 was
significantly correlated to CXCL16 (r = 0.531, p = 0.000).
At 24 weeks of therapy CXCL5 was significantly corre-
lated to CXCL9 (r = 0.327, p = 0.027), CXCL11 (r = 0.587,se to treatment
Pegylated interferon α 2a
(PEGASYS) (n=19)
P-value
(n=19) Non-responders (n=9) Responders (n=10)
92903 1.22044 ± 1.022862 1.42330 ± .925645 0.000a, 0.602b,
0.875c, 0.770d,
0.345e, 0.703f8673 1.00456 ± .699765 .80800 ± .609552
06 .7664 ± .43326 .8625 ± .63422
6974 .18922 ± .074028 .18810 ± .063218 0.082a, 0.744b,
0.415c, 0.962d,
0.199e, 0.517f0243 .16744 ± .127693 .12573 ± .053301
1548 .15544 ± .097306 .13464 ± .055773
2608 .17885 ± .093798 .15742 ± .100730 0.187a, 0.584b,
0.459c, 0.435d,
0.065e, 0.634f8519 .17154 ± .049891 .19991 ± .152004
2551 .12744 ± .044230 .19255 ± .161593
4332 .55400 ± .244147 .45300 ± .163781 0.117a, 0.085b,
0.085c, 0.229d,
0.065e, 0.085f7961 .54833 ± .196068 .43490 ± .205439
.496 ± .1217 .42900 ± .1590
5584 .40567 ± .274538 .29844 ± .105315 0.002a, 0.085b,
0.085c, 0.229d,
0.065e, 0.085f6432 .52944 ± .271026 .34133 ± .145816
7348 .62800 ± .455588 .39955 ± .128076
4527 1.14611 ± .424545 1.01250 ± .331579 0.000a, 0.221b,
0.527c, 0.689d,
0.577e, 0.866f23698 1.25411 ± .342009 1.24990 ± .417217
08803 1.29189 ± .354069 1.28820 ± .402766
6687 .82833 ± .843119 .68330 ± .660015 0.140a, 0.274b,
0.749c, 0.504d,
0.578e, 0.794f7851 .92678 ± .782186 .74020 ± .657444
8560 .81578 ± .834449 .81032 ± .779431
-type interaction d, time-response interaction e, type-response interaction f.
(a) 
(b)  
Figure 1 CXCL-5 levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
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nificantly correlated to CXCL9 (r = 0.311, p = 0.036),
CXCL12 (r = 0.494, p = 0.000), CXCL16 (r = 0.400, p =
0.006) and E-cadherin (r = 0.454, p = 0.002) while CXCL12
was significantly correlated to CXCL16 (r = 0.634, p =
0.000) and E-cadherin (r = 0.777, p = 0.000). CXCL16 was
significantly correlated to E-cadherin (r = 0.861, p = 0.000).
Both CXCL16 and E-cadherin were significantly correlated
to ALT levels (r = 0.319, p = 0.031) and (r = 0.350, p =
0.017); respectively.
Discussion
Previous studies have investigated pretreatment predic-
tors of response to interferon based therapy in HCV-associated CHC patients. Some of these studies have
shown that cytokines could be used as predictors of
treatment outcome [17].
In the current study, different baseline data that might
affect the achievement of SVR and different chemokines
levels were analyzed at different time intervals from
starting therapy. We were able to show a statistically
significant difference between responders and nonre-
sponders to peg-intron and pegasys therapy in relation
to AFP and AST values. Assessment of the correlation
between the expression levels of these chemokine’s and
response to treatment at baseline, week 12, and 24
revealed that the baseline serum level of CXCL5 was sig-
nificantly higher than those after 12 or 24 weeks from
Table 4 Different chemokine’s levels of 55 patients at 12 weeks in response to treatment
Parameter Pegylated interferon α 2b
(PEG-INTRON) (n=31)
Pegylated interferon α 2a
(PEGASYS) (n=24)
P-value
Non-responders (n=10) Responders (n=21) Non-responders (n=13) Responders (n=11)
CXCL5(pg/ml) Pretreatment 1.45250 ± 940684 1.30990 ± .759433 1.44500 ± 1.077797 1.43018 ± .878441 0.000a, 0.486b,
0.593c, 0.236d,
0.665e, 0.552f12 Weeks .71740 ± .377958 .88486 ± .588673 1.25877 ± 851592 .80655 ± .578292
CXCL9(pg/ml) Pretreatment .20700 ± .102838 .19700 ± .078764 .19854 ± .134327 .18836 ± .059980 0.492a, 0.555b,
0.256c, 0.239d,
0.174e, 0.393f12 Weeks .15520 ± .105935 .14029 ± .039694 .28985 ± .489042 .12573 ± .053301
CXCL11(pg/ml) Pretreatment .13520 ± .080444 .13905 ± .074375 .17885 ± .093798 .16373 ± .103128 0.144a, 0.190b,
0.787c, 0.435d,
0.065e, 0.634f12 Weeks .15260 ± .081185 .16190 ± .098519 .17154 ± .049891 .19991 ± .152004
CXCL12(pg/ml) Pretreatment 51.01730 ± 206.396544 .39581 ± .154332 .58746 ± .244147 .43218 ± .163781 0.187a, 0.185b,
0.182c, 0.229d,
0.065e, 0.188f12 Weeks .50380 ± .065023 .42181 ± .147961 .61662 ± .196068 .42227 ± .205439
CXCL13(pg/ml) Pretreatment .35510 ± .069974 .31505 ± .105584 .45677 ± .274538 .29830 ± .105315 0.001a, 0.753b,
0.017c, 0.329d,
0.251e, 0.072f12 Weeks .49510 ± .139194 .42638 ± .246432 .56569 ± .271026 .33490 ± .145816
CXCL16(ng/ml) Pretreatment 1.00250 ± .101567 .87652 ± .244527 1.16792 ± .424545 1.01791 ± .331579 0.000a, 0.081b,
0.227c, 0.689d,
0.378e, 0.702f12 Weeks 1.12440 ± .298719 1.11633 ± .323698 1.36885 ± .342009 1.23936 ± .417217
E-cadherin(ng/ml) Pretreatment .82420 ± .425530 .47852 ± .436687 .98600 ± .843119 .63418 ± .660015 0.240a, 0.426b,
0.041c, 0.864d,
0.748e, 0.794f12 Weeks .95180 ± .666040 .55862 ± .577851 1.09185 ± .782186 .68536 ± .657444
p-value comparing the effect of time a, treatment type b, response to treatment c, time-type interaction d, time-response interaction e, type-response interaction f.
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for responders and non-responders but with no significant
correlation with response to treatment. This could be
attributed to an interaction between immune response
and viral activity, which is indicated by the differences in
cytokines and chemokine’s expression during the course
of treatment [20]. On the other hand, Dou et al., [21]
demonstrated that the HCV-2a core protein was shown to
down-regulated CXCL5 gene in human hepatoma (Huh-7)
cell line.
Our results regarding the decrease in the CXCL9 level
in responders to pegylated interferon α 2 b and α 2 a
therapy after 12 and 24 weeks are consistent with those
of Wan et al., [20] who demonstrated that serum CXCL9
levels decreased significantly after the initiation of IFN
therapy indicating a possible effect on the rate of viral
clearance. On the other hand Butera et al., [22] found
that pretreatment samples showed no consistent differ-
ences in CXCL9 level between patients who subsequently
failed therapy and those who subsequently developed
asustained response to antiviral therapy. They also found
that CXCL9 level declined during therapy in both
responders and non-responders. Among sustained re-
sponders, CXCL9 level remained low after completion of
therapy while in non-responders, the drop in CXCL9 was
transient. A possible explanation for the difference be-
tween our results and the later study could be our smaller
sample size and the fact that all our patients were geno-
type 4.Our data regarding the elevated CXCL11 level in re-
sponders of peg-intron therapy at 12 and 24 weeks,
followed by a decrease at 12 weeks then an increase at
24 weeks for both responders and non-responders of
pegasys therapy with no significant difference regarding
time effect, treatment type, and response to treatment
contrast with those of Butera et al., [22] who found that
CXCL11 level measurement was lower in those who
subsequently achieved SVR than in those who subse-
quently have no reduction in HCV RNA during or after
antiviral therapy but with no significant differences in
response. Therefore, they concluded that there was no
association between pretreatment levels of CXCL11 and
the outcome of treatment. The increase in CXCL11 level
in the current study may be related to an increase in its
receptor (CXCR3) levels in CHC patients as previously
mentioned by Perney et al., [23]. We also reported a
slightly increase in CXCL12 level was responders to
PEG-IFN α2b therapy at 12 weeks and a decrease in
non-responders and in all patients receiving PEG-IFN
α2a after 12 and 24 weeks. Cicinnati et al., [24] have pre-
viously mentioned that IFN-α can modulate the expres-
sion of G protein coupled chemokine receptors, and
some adhesion molecules, which are required for den-
dritic cell (DC) trafficking into secondary lymphoid tis-
sue. Accordingly, the effect of IFN on CXCL12 levels, in
the current study, could be explained by IFN-α therapy-
induced migration of DC from inflamed hepatic portal
areas towards secondary lymphoid tissue with increased
(a)
(b)
Figure 2 CXCL-9 levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
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ing the significant reduction of pretreatment CXCL13
level was with time of interferon treatment for both re-
sponders and non-responders regardless of treatment type
are consistent with Sansonno et al. [25] who mentioned
that up-regulation of CXCL13 gene expression is a dis-
tinctive feature of HCV-infected patients. Therefore high
levels of this chemokine could be detected in the liver and
skin of patients with CHC and these levels might decrease
after therapy.
In our patients, pretreatment CXCL16 level increased
significantly with time in responders and non-responders
to pegylated interferon α2b and α2a therapy with no sig-
nificant difference between the two groups. This could be
attributed to the effect of IFN, which improves TH-1
response [26]. IFN-α treatment has been shown to regu-
late the activity of other cytokines and chemokines either
directly or indirectly [27].Alteration in E-Cadherin expression has been associ-
ated with human carcinogenesis including HCC [28]. In
our series, E-Cadherin increased in non-responders and
responders to Pegylated IFNα 2a or 2b after 12 weeks
from the beginning of therapy however it continued to
increase at 24 weeks only in responders of both groups.
This could be attributed to the effect of HCV core pro-
tein, which represses E-Cadherin expression at the tran-
scriptional level by down-regulating its promoter activity
through promoter hypermethylation [29]. The significant
difference in serum levels of E-Cadherin, reported in our
study, at week 12 between responders and non-responders
shows that it could be used as a predictor of EVR in IFN-
treated CHC patients.
No significant correlation was found in the current
study between any of the studied chemokines levels and
baseline HCV RNA. On the other hand, baseline data
have shown significant correlations between CXCL9 and
(b)
(a)
Figure 3 CXCL-11 levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
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CXCL16 and E-cadherin, as well as between ALT level
and E-cadherin that were maintained in follow up results.
In other words, these significant correlations were pre-
sent at pretreatment, after 12 weeks, and after 24 weeks.
In a previous study done by Butera et al., [22] stated that
there was no correlations between CXCL9 and CXCL11
chemokines levels and viral load. On the other hand,
Perney et al., [23] found a correlation between the expres-
sion of CXCR3 on peripheral blood CD4+ T cells and
AST serum levels. Cicinnati et al., [24] also found that
there were no significant correlations between systemic
levels of CXCL12 and gender, age, grade of hepatic inflam-
mation, stage of fibrosis, transaminases, bilirubin, HCV
genotype or viral load. Also, Sansonno et al., [25] found
that there was no correlation between CXCL13 concentra-
tions and circulating viral load or ALT levels. One of the
explanations for these findings is the lack of a direct effect
of the virus on the sources of CXCL13 production.Conclusion
In conclusion, our results have shown that serum levels of
CXCL13 and E-Cadherin have the potential to be used as
serological markers at week 12 to the response of com-
bined PEG IFN- α/RBV therapy. Also, significant changes
with time have been found in the serum levels of CXCL5,
CXCL13, and CXCL16 before pegylated interferon α 2 a
and α 2 b therapy, and at weeks 12 and 24 with no signifi-
cant difference in relation to treatment type, response
to treatment, time-type interaction, time-response inter-
action, or type-response interaction. However, there were
some limitations of our study, as example, this study
should be done on a large scale in order to be validated.
Also, it is better to apply one type of PEG-IFN prepara-
tions, and avoiding confounding was not an easy task,
when assessing the association between tested chemokines
and an outcome variable which leads to an overestimate




Figure 4 CXCL-12 levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
Zekri et al. Virology Journal 2013, 10:218 Page 9 of 14
http://www.virologyj.com/content/10/1/218Methods
Patients
This prospective study included 57 patients with chronic
HCV (CHC) liver disease. These patients constituted a
part of a randomized controlled study including 200
patients receiving either pegylated interferon α 2b or
pegylated interferon α 2a in combination with ribavirin
during the period from September 2006 to March 2009.
A written informed consent for immunological research,
in which patients were assigned to give 10 mL of venous
blood at each studied point during the course of therapy,
blood was obtained from all patients before enrollment
in the study. Only 57 patients accepted to share in the
current study (32 received pegylated interferon α 2b and
25 received pegylated interferon α 2a, at baseline and
after 12 and 24 weeks). All patients were treated in Al
Qahira Al Fatimia Hospital (a district hospital at the
middle of Cairo) as a part of the national program forcombating viral hepatitis under supervision and sponsor-
ship of The Ministry of Health. A written consent was
obtained from all patients prior to enrollment in the
study and the ethical committee of Al Qahira Al Fatimia
Hospital and Ministry of Health approved the protocol,
which was in accordance with the ethical guidelines of
the Helsinki Declaration.
Selection criteria included male or female patients with
CHC, aged 18 years or older with HBsAg negative, anti-
nuclear antibody (ANA) <1:160, positive anti-HCV anti-
bodies and HCV RNA by RT-PCR. All patients had white
blood cells (WBCs) > 4000/mm3, neutrophil count >2000/
mm3, platelets >75 000/mm3, prothrombin time <2 sec-
onds above the upper limit of normal (ULN), direct biliru-
bin 0.3 mg/dL or within 20% of ULN, albumin >3.5, alpha
fetoprotein <100, serum creatinine within normal limit
(WNL), fasting blood sugar 115 mg/dl or within 20% ULN
and if diabetic Hb A1C < 8.5% with normal T3, T4 and
(a)
(b)
Figure 5 CXCL-13 levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
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http://www.virologyj.com/content/10/1/218TSH. On the other hand, patients with decompensated
liver disease or those with chronic liver disease due to
causes other than HCV e.g. HBV, alpha-1 antitrypsin defi-
ciency, Wilson’s disease, haemochromatosis, alcoholic liver
disease or autoimmune disease were excluded from the
study. Similarly, patients with hypersensitivity to inter-
feron or ribavirin, pregnant or breast feeding females and
those with any co-morbid conditions were excluded. All
patients were subjected to full history taking and clinical
assessment, routine laboratory work up including com-
plete blood picture, liver biochemical profile, serum urea
and creatinine, blood glucose, pregnancy test for married
females, HBsAg, ANA, TSH, AFP and anti-schistosomal
Ab titer. ECG was done for males > 40 years and fe-
males >50 years old. Ocular examination and abdom-
inal ultrasound were also done.Follow up and monitoring response to antiviral ther-
apy was done on week 1, 2 and 4 after initiation of ther-
apy then every 4 weeks. During each follow up, signs
and symptoms of possible adverse effects due to the
drugs were evaluated by routine laboratory studies. If
treatment was continued in the presence of adverse
effects, either dose adjustments were considered or the
particular side effect was treated or monitored without
lowering dosages depending on its severity.
Quantitative HCV RNA by Real time-polymerase chain
reaction (RT-PCR) was performed after 12 weeks of ther-
apy to determine Early Virological Response (EVR) upon
which the decision to continue treatment after 12 weeks
was taken, in addition to the patients’ tolerance to drugs
and laboratory profile. Qualitative HCV viral load was also
done after 24 weeks of treatment and if negative, the
(a)
(b)
Figure 6 CXCL-16 levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
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http://www.virologyj.com/content/10/1/218patient continued on the treatment. It was also done once
the course of treatment was completed to document the
End of Treatment Response (ETR). Sustained Virological
Response (SVR) was defined as the absence of detectable
HCV RNA in serum at the 24th week after the end of
treatment [30].
Quantitative real time PCR for determination of
HCV viremia
RNA was extracted from patients’ blood using the
QIAmp Viral RNA Mini Kit (QIAGEN, Santa Clarita, U.
S.A) according to the manufacturer’s instructions, then
quantitative Real time-polymerase chain reaction (RT-PCR)
was performed using previously standardized realtime RT-
PCR protocol for HCV, supplied from applied biosystems
(USA) and according to Zekri et al. [31].
HCV genotyping
HCV genotyping was done using the INNOLIPA–II
technique as previously described by Zekri et al. [32].Monitoring patients’ response to therapy
Responses to therapy in patients with HCV were de-
termined according to the consensus guidelines of the
National Institutes of Health. Responders to therapy
were defined by normalization of serum alanine amino-
transferase (ALT) and absence of detectable serum HCV
RNA at the end of treatment (48 weeks). Relapsed re-
sponders to therapy were defined by normalization of
serum ALT and absence of detectable serum HCV RNA
at the end of treatment but with an increase of the
serum ALT and the presence of HCV RNA at follow-up
(72 weeks). Non-responders were defined by elevated
serum ALT and the presence of HCV RNA at the end of
treatment.
Assay of chemokines
Ten ml of blood were obtained from patients for serum
separation before the start of therapy, after 12 and
24 weeks of therapy. CXCL5, CXCL9, CXCL11, CXCL12,
CXCL 13, CXCL 16 chemokines and E-Cadherin were
(a)
(b)
Figure 7 E-cadherin levels in responders and non responders to a) PEG-Interferone and, b) pegasys at different time intervals.
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kits used were provided by Quantikine kits (R&D Systems,
Inc. 614 McKinley Place NE Minneapolis, MN 55413
United States of America), sponsored by NCI and used
according to the manufacturer’s instructions.
Histopathological examination
Pretreatment liver biopsies from all patients were exam-
ined to confirm the diagnosis and determine the stage of
fibrosis and the grade of inflammation using Modified
Knodell score [33], in the form of 18 points for histo-
pathology activity index (HAI), six points for stage of
fibrosis and four points for stage of steatosis [34].
The histological activity index in the studied patients
were graded into minimal (0–3), mild (4–8), moderate(9–12) and severe (13–18) points. The stage of fibrosis
was graded into minimal (0–1), moderate (2–4) and
marked (5–6) points.
Statistical methods
Statistical analysis was done using SPSS version 17 statis-
tical software package for windows. Quantitative variables
were expressed by mean and SD (Standard deviation),
comparison of means using Student’s t-test, Mann–Whitney
U-test or ANOVA test were done when appropriate.
Time-type interaction, time-response interaction, or type-
response interaction were measured and analyzed statisti-
cally by repeated measures analysis of variance. In the
table of multivariate tests, we took into consideration
the p-values (for Wilks Lamda), and partial Eta square
Zekri et al. Virology Journal 2013, 10:218 Page 13 of 14
http://www.virologyj.com/content/10/1/218(according to Cohen’s standard) for measuring the interac-
tions and their effect size. MANOVA was used under the
same circumstances as ANOVA but when there were mul-
tiple dependent variables as well as independent variables
within the model which the researcher wishes to test.
MANOVA is also considered a valid alternative to the re-
peated measures ANOVA when sphericity was violated.
Also, Pearson correlation test was performed for correlating
quantitative variables. Qualitative variables were expressed
by frequency and percent, comparison of mean values and
assessment of relations using chisquared test or Fisher’s
exact test was done when appropriate. P-value was consid-
ered significant when < 0.05 significant and highly signifi-
cant when < 0.01.
Abbreviation
ALT: Serum alanine aminotransferase; ANA: Anti-nuclear antibody;
AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; CHC: Chronic
hepatitis C; DC: Dendritic cells; EVR: Early virological response; ETR: End of
treatment response; HAI: Histopathology activity index; HCC: Hepatocellular
carcinoma; HCV: Hepatitis C virus; HBsAg: Hepatitis B surface antigen; PEG
IFN-α/RBV: Pegylated interferon-alpha and ribavirin; SD: Standard deviation;
SVR: Sustained virological response; TSH: Thyroid stimulating hormone;
ULN: Upper limit of normal; WBCs: White blood cells; WHO: World health
organization; WNL: Within normal limit.
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